Intravitreal Bevacizumab for Diabetic Macular Edema

This study is enrolling participants by invitation only.

Sponsor:

Information provided by:

Isfahan Ophthalmology Research Center

ClinicalTrials.gov Identifier:

NCT00703235

First received: June 20, 2008

Last updated: NA

Last verified: June 2008

History: No changes posted

Tracking Information
First Received Date ^ICMJE	June 20, 2008
Last Updated Date	June 20, 2008
Start Date ^ICMJE	Not Provided
Primary Completion Date	Not Provided
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	No Changes Posted
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Intravitreal Bevacizumab for Diabetic Macular Edema
Official Title ^ICMJE	Not Provided
Brief Summary	Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 2 Phase 3
Study Design ^ICMJE	Not Provided
Condition ^ICMJE	Macular Edema Diabetic Retinopathy
Intervention ^ICMJE	Drug: Bevacizumab
Study Arm (s)	Not Provided
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Enrolling by invitation
Enrollment ^ICMJE	Not Provided
Completion Date	Not Provided
Primary Completion Date	Not Provided
Eligibility Criteria ^ICMJE	Inclusion Criteria: Diabetes mellitus Clinically significant macular edema Possibility of performing macular OCT Consent of patient for inclusion in the study Exclusion Criteria: History of macular photocoagulation in less than 6 months of inclusion in the study Necessity of surgical intervention Rejection of the remaining in the study by patient
Gender	Both
Ages	Not Provided
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Not Provided

Administrative Information
NCT Number ^ICMJE	NCT00703235
Other Study ID Numbers ^ICMJE	MUI - clinical - 185290
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Isfahan Ophthalmology Research Center
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Isfahan Ophthalmology Research Center
Verification Date	June 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top